East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) will be exhibiting at CPhI Worldwide 2014, October 7 - 9 in Paris Nord Villepinte, France.
Conference delegates are warmly invited to visit Cambrex’s booth to learn more about our extensive list of generic Active Pharmaceutical Ingredient (API) products, as well as, process development and custom manufacturing services for API and Drug Product Formulation.
Cambrex will have representatives from sales, business development and its sites in Italy, US, Sweden, Germany, Estonia and India available for discussions with customers about global supply from clinical through launch and commercial stages.
Generic APIs: Extensive list of over 100 APIs at commercial and development stages meeting the highest quality standards and global registration requirements.
Custom Manufacturing: Classic and advanced chemistry, world-class quality systems and outstanding regulatory inspection record.
High Potency APIs (HPAPIs): Development and manufacturing of cytotoxic and oncology APIs.
High Energy Chemistries: Development and manufacturing of high energy and thermally unstable products
Large-scale Biocatalysis: Enzyme screening and custom biocatalysis development and manufacturing capabilities
Controlled Substance APIs: Licenses to import, develop, manufacture and distribute US DEA Schedule II-V controlled substances.
Drug Delivery: API + Polymer composite products that are tasteless, colorless and improve drug stabilization and release control in oral dose formulations.
Drug Product Formulations: Proprietary Nicotine Replacement Therapy (NRT) products and solid dosage form custom development and manufacturing, including gums and lozenges.
Four world-class fully-inspected production sites approved for commercial production in US, Europe and India
Outstanding regulatory history at each site
Hundreds of APIs and intermediates manufactured under cGMP
Routinely audited by the US FDA and EMA
Cambrex will be exhibiting in Hall 6, Stand 6F129. We look forwarding to welcoming you.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.